Celcuity (CELC) Stock Price, News & Analysis

Company Overview

Celcuity, Inc. is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways. These assays are intended to serve as companion diagnostics, guiding the use of therapies such as PARP inhibitors and other targeted molecules in oncology. In addition to its core diagnostic offerings, Celcuity collaborates with pharmaceutical companies to co-develop new companion tests alongside emerging drug candidates, aiming to streamline clinical development and regulatory approval.

Headquartered in Malvern, Pennsylvania, Celcuity was founded in the mid-2000s by a team of scientists and clinicians with extensive experience in cancer biology and diagnostic innovation. The company’s operations are primarily focused on the North American market, where it provides testing services through its CAP-accredited and CLIA-registered laboratory. Celcuity’s leadership team brings together expertise in biopharma partnerships, clinical diagnostics, and regulatory affairs to advance its pipeline of precision oncology solutions.

Key Stats

• Today's Range: $127.75 to $135.80
• 50-Day Range: $102.01 to $141.69
• 52-Week Range: $10.26 to $151.02
• Volume: 640,879 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $6.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $149.30
• Consensus Rating: Moderate Buy

Celcuity Stock Analysis - MarketRank™

Celcuity scored higher than 46% of companies evaluated by MarketBeat, and ranked 649th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Celcuity has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Celcuity has a consensus price target of $149.30, representing about 13.9% upside from its current price of $131.09.

Amount of Analyst Coverage

Celcuity has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Celcuity are expected to grow in the coming year, from ($3.87) to $0.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celcuity is -33.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celcuity is -33.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celcuity has a P/B Ratio of 119.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.31% of the float of Celcuity has been sold short.

Short Interest Ratio / Days to Cover

Celcuity has a short interest ratio ("days to cover") of 11.17, which indicates bearish sentiment.

Change versus previous month

Short interest in Celcuity has recently increased by 1.40%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celcuity does not currently pay a dividend.

Dividend Growth

Celcuity does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.35

News Sentiment

Celcuity has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Celcuity this week, compared to 5 articles on an average week.

Search Interest

12 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.

MarketBeat Follows

5 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,111,950.00 in company stock.

Percentage Held by Insiders

13.33% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CELC
• CIK: 1603454
• Web: www.celcuity.com
• Phone: (763) 392-0767
• Fax: N/A
• Employees: 40
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Celcuity: $149.30
• High Price Target: $189.00
• Low Price Target: $60.00
• Potential Upside/Downside: +13.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$177.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -244.61%
• Return on Assets: -50.22%

Debt

• Debt-to-Equity Ratio: 6.04
• Current Ratio: 12.31
• Quick Ratio: 12.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: 119.17

Miscellaneous

• Outstanding Shares: 48,770,000
• Free Float: 42,265,000
• Market Cap: $6.39 billion
• Optionable: Optionable
• Beta: 0.09